Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population

Abstract

The present study provides valuable evidence for the safety and effectiveness of switching from originator to biosimilar infliximab over a prolonged period of 18 months and demonstrates that switching was well tolerated and did not affect the long term clinical outcome.